Stuart A. Tross Sells 25,000 Shares of MannKind Co. (NASDAQ:MNKD) Stock

MannKind Co. (NASDAQ:MNKD) insider Stuart A. Tross sold 25,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.26, for a total transaction of $156,500.00. Following the sale, the insider now directly owns 1,022,191 shares in the company, valued at approximately $6,398,915.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

MannKind Stock Performance

NASDAQ:MNKD opened at $6.03 on Friday. MannKind Co. has a 52 week low of $3.17 and a 52 week high of $6.44. The firm’s fifty day moving average is $5.53 and its 200-day moving average is $4.85. The firm has a market cap of $1.64 billion, a P/E ratio of 201.00 and a beta of 1.32.

MannKind (NASDAQ:MNKD) last issued its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. The firm had revenue of $72.39 million during the quarter, compared to the consensus estimate of $64.81 million. MannKind had a negative return on equity of 11.97% and a net margin of 4.73%. The business’s revenue was up 48.9% compared to the same quarter last year. During the same period last year, the business posted ($0.02) EPS. As a group, sell-side analysts anticipate that MannKind Co. will post 0.11 earnings per share for the current year.

Hedge Funds Weigh In On MannKind

Several institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. bought a new stake in shares of MannKind in the 2nd quarter valued at $55,000. 9258 Wealth Management LLC bought a new stake in MannKind in the first quarter valued at $51,000. Brookstone Capital Management acquired a new position in shares of MannKind during the second quarter valued at about $61,000. Renaissance Technologies LLC bought a new position in shares of MannKind during the 2nd quarter worth about $67,000. Finally, EntryPoint Capital LLC grew its stake in shares of MannKind by 60.9% in the 1st quarter. EntryPoint Capital LLC now owns 23,809 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 9,008 shares during the period. 49.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MNKD shares. Rodman & Renshaw assumed coverage on MannKind in a report on Thursday, June 13th. They set a “buy” rating and a $8.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $6.50 price target on shares of MannKind in a research note on Thursday, May 9th. Finally, Oppenheimer upped their price objective on MannKind from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Wednesday, August 28th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, MannKind currently has a consensus rating of “Moderate Buy” and an average target price of $8.80.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.